Short Interest in Compugen Ltd. (NASDAQ:CGEN) Decreases By 17.1%

Compugen Ltd. (NASDAQ:CGEN - Get Free Report) saw a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 1,550,000 shares, a decrease of 17.1% from the September 30th total of 1,870,000 shares. Based on an average daily volume of 231,800 shares, the days-to-cover ratio is presently 6.7 days.

Compugen Stock Down 1.2 %

Shares of NASDAQ CGEN traded down $0.02 during trading on Tuesday, hitting $1.67. The company had a trading volume of 63,089 shares, compared to its average volume of 411,766. The firm has a market capitalization of $149.03 million, a price-to-earnings ratio of -8.79 and a beta of 2.64. The stock has a fifty day simple moving average of $1.84 and a two-hundred day simple moving average of $1.90. Compugen has a fifty-two week low of $0.53 and a fifty-two week high of $3.03.

Compugen (NASDAQ:CGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.06. The firm had revenue of $6.70 million for the quarter, compared to analysts' expectations of $2.68 million. During the same quarter last year, the firm posted ($0.11) earnings per share. On average, analysts anticipate that Compugen will post 0.15 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Compugen from a "hold" rating to a "buy" rating in a research report on Thursday, August 15th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rothschild Investment LLC acquired a new stake in shares of Compugen in the second quarter valued at approximately $380,000. ARK Investment Management LLC grew its holdings in Compugen by 4.7% in the 2nd quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company's stock valued at $1,850,000 after buying an additional 48,979 shares in the last quarter. Secure Asset Management LLC acquired a new stake in shares of Compugen in the 2nd quarter worth $69,000. Joel Isaacson & Co. LLC raised its holdings in shares of Compugen by 136.4% during the 3rd quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company's stock worth $94,000 after acquiring an additional 30,000 shares during the period. Finally, Squarepoint Ops LLC boosted its position in shares of Compugen by 23.4% during the 2nd quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company's stock valued at $144,000 after acquiring an additional 16,253 shares during the last quarter. Hedge funds and other institutional investors own 12.22% of the company's stock.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.